Supplements for migraine sufferers

Evidence-based picks for migraine prevention — AAN-graded stack plus what to skip.

Migraine is the rare condition with American Academy of Neurology (AAN) guideline support for several specific supplements as preventive therapy: magnesium (Level B / probably effective), riboflavin (Level B), CoQ10 (Level C / possibly effective), and feverfew (Level B for certain extracts). The 2024 update of preventive evidence continues to support these picks for people with 4+ migraine days/month who want to reduce frequency without prescription preventives, or as adjuncts to them. Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and gepants have transformed care in the past 5 years — supplements are first-line for mild/moderate-frequency migraine and adjuncts at higher frequencies.

Magnesium (citrate or glycinate)

Prevention · AAN Level B · 400–600 mg/day

Tier 1

Riboflavin (Vitamin B2)

Prevention · AAN Level B · 400 mg/day

Tier 2

CoQ10 (Ubiquinol)

Prevention · AAN Level C · 100 mg t.i.d.

Tier 2

Omega-3 (EPA/DHA)

Adjunct · 2024 BMJ trial signal

Tier 1

Melatonin (3 mg)

Prevention · Sleep-pattern stabilisation

Tier 2

Feverfew (MIG-99 stabilised extract)

Prevention · AAN Level B (specific extract)

Tier 2

Vitamin D3

Often deficient in chronic migraine

Tier 1

Ginger (acute)

Acute nausea · Migraine adjunct

Tier 1

The migraine prevention stack — by evidence layer

Magnesium 400–600 mg/day elemental (AAN Level B)

Three RCTs and the AAN guideline support magnesium for migraine prevention at 400–600 mg/day. Citrate or glycinate forms; avoid oxide for systemic effect. Effect develops over 8–12 weeks. Most useful in menstrual migraine and aura-prominent patterns. Start at 200 mg/day, titrate up. Loose stools is the dose-limiting issue.

Riboflavin (Vitamin B2) 400 mg/day (AAN Level B)

Schoenen 1998 RCT and subsequent trials show riboflavin 400 mg/day reduces migraine frequency. The dose is much higher than RDA (1.3 mg) — riboflavin is water-soluble and very well tolerated; the only common side effect is bright-yellow urine. Effect develops over 8–12 weeks. Particularly strong evidence in paediatric and adolescent migraine (Bruijn 2010).

CoQ10 ubiquinol 100 mg t.i.d. (AAN Level C)

Sandor 2005 RCT showed CoQ10 300 mg/day reduced migraine days vs placebo. Pediatric data also support use. Effect via mitochondrial energy support; develops over 12 weeks. Take with fat-containing meal. Particularly useful in migraine with cognitive prodrome or fatigue features.

Omega-3 (EPA/DHA) 1.5 g EPA + DHA daily

Ramsden 2021 BMJ trial showed high-omega-3 + low-omega-6 dietary pattern reduced migraine days by ~30% vs control. Trial used dietary plus supplemental approach. Supplement-only approach is less validated but a reasonable adjunct. DHA-emphasised products preferred.

Melatonin 3 mg at bedtime

Gonçalves 2016 trial showed melatonin 3 mg comparable to amitriptyline for migraine prevention. Particularly useful in cases with sleep-onset disruption or jet-lag-triggered migraine. The 3 mg dose specifically is the trial-evidenced dose.

Vitamin D3 — test and correct

Several observational studies show higher migraine prevalence in vitamin D deficiency. Test 25-OH-D; supplement to 30–50 ng/mL. Modest contribution to prevention but cheap to correct.

Feverfew (MIG-99 stabilised extract) 6.25 mg t.i.d.

The 2005 Diener trial of MIG-99 (a stabilised feverfew extract) showed migraine-day reduction vs placebo. AAN Level B for this specific extract; generic feverfew preparations have inconsistent parthenolide content and inconsistent trial results.

Ginger 500 mg–1 g (acute migraine adjunct)

Maghbooli 2014 trial: ginger 250 mg comparable to sumatriptan for acute migraine in some endpoints. Also reduces nausea component. Useful as an acute add-on, not prevention.

For menstrual-pattern migraine

Magnesium 400 mg/day continuous + perimenstrual 1–2-day boost; vitamin B6 (P5P) 50 mg/day adjunct; consider perimenstrual NSAID or triptan loading with your prescriber.

What to skip

Butterbur (petasites) — was AAN Level A but the FDA, ESCOP, and AAN have since withdrawn recommendations due to hepatotoxicity from contaminated products. The PA-free preparations claimed to be safe are not reliably so.
Magnesium oxide (for systemic effect) — poorly absorbed; acts as a laxative. Use citrate, glycinate, malate, or threonate for migraine.
5-HTP for migraine prevention — limited evidence; serotonin-syndrome concern with triptans makes the combination potentially risky.
Frequent OTC analgesic use (NSAIDs, paracetamol, mixed-codeine products) — >10–15 days/month drives medication-overuse headache. Track use carefully.
Generic "migraine support" blends — often subtherapeutic doses of relevant ingredients; the trial-evidenced single-ingredient doses outperform.
Aspartame-heavy diet sodas — common migraine trigger in susceptible individuals; not a supplement note but worth eliminating during trigger investigation.

Educational reference, not medical advice. Discuss any supplement change with a qualified clinician before acting on this list. New severe headache, headache with neurological features, or significantly changed headache pattern warrants urgent evaluation. For ≥8 migraine days/month, anti-CGRP therapy and modern preventives outperform supplement-only strategies in trial data — supplements are still a reasonable adjunct.

Sources

Holland S, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: AAN/AHS guideline. Neurology. 2012;78(17):1346–1353. PMID: 22529203
Schoenen J, et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50(2):466–470. PMID: 9484373
Sandor PS, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–715. PMID: 15728298
Peikert A, et al. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–263. PMID: 8792038
Ramsden CE, et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. 2021;374:n1448. PMID: 34526307
Diener HC, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041. PMID: 16232154
Maghbooli M, et al. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytother Res. 2014;28(3):412–415. PMID: 23657930